Media Info
News Release: 1700 hours CET, Wednesday 18 March 2009
‘PSA Screening Cuts Deaths by 20%, says ERSPC, World’s Largest Prostate Cancer Study’
Screening for prostate cancer can reduce deaths by 20%, according to the results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) published by NEJM, Online First. ERSPC is the world’s largest prostate cancer screening study and provides robust, independently- audited evidence, for the first time, of the effect of screening on prostate cancer mortality. >more
Explanatory Notes
- ERSPC – background
- PSA – the test
- Over diagnosis, Active Surveillance & Prias Project
- Screening Suitability
- Mortality reduction percentage
- Funding
- Copy of full paper on NEJM Online First
Media info:
Jennie Wilde, ERSPC press office: +44 20 3178 5563 or +44 7799 412230,
email: jennie@carverwilde.com
Lindy Brouwer, EAU press office: + 46 765460750